The Predictive Value of BUB1 in the Prognosis of Oral Squamous Cell Carcinoma.

Background: Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumour in the oral cavity, and it is known for its poor prognosis. Budding uninhibited by benzimidazoles 1 (BUB1) may be related to cancer prognosis; however, the specific relationship between BUB1 and OSCC prognosis remains largely unexplored.

Methods: The mRNA levels of BUB1 were analysed using data from the TCGA_OSCC and GSE23558 cohorts. OSCC samples from the TCGA_OSCC dataset were divided into low- and high-BUB1 expression groups based on the median BUB1 level. Furthermore, results of survival analysis, tumour mutation burden (TMB), gene set enrichment analysis (GSEA) pathways, and drug-sensitivity analysis were compared between the 2 groups.

Results: Based on the data from the TCGA_OSCC and GSE23558 cohorts, BUB1 mRNA levels were significantly upregulated in OSCC tissues compared to healthy controls. Moreover, high expression of BUB1 may serve as an independent indicator of poor prognosis in OSCC. Additionally, patients with high BUB1 expression also exhibited increased levels of immune checkpoints and TMB, suggesting that patients with high BUB1 expression may benefit from immunotherapy. Mechanistically, transcription factors ZFP64, TCF3, and ZNF281 were found to potentially bind to the promoter region of BUB1, thereby regulating its gene expression. Furthermore, GSEA results showed that BUB1 expression was closely related to cell cycle and tumour-related pathways in OSCC. Drug-sensitivity analysis showed that patients with high BUB1 expression may be more sensitive to gemcitabine, paclitaxel, or imatinib.

Conclusions: Collectively, results demonstrated that high BUB1 levels may be related to a poor prognosis of OSCC, highlighting its potential as a novel prognostic biomarker for OSCC.